About Human Metapneumovirus | Human Metapneumovirus
Aug 15, 2016 · Infection with HMPV can be confirmed usually by. direct detection of viral antigens in respiratory secretions using immunofluorescence or enzyme immunoassay. Currently, there is no specific antiviral therapy to treat HMPV and no vaccine to …
Human metapneumovirus (hMPV) infection - World Health …
Jan 10, 2025 · There is currently no vaccine licensed for use against hMPV, but research is ongoing. How is hMPV infection treated? As hMPV is a cold virus, people can treat their symptoms with over-the-counter medicines to treat pain, fever, stuffy nose and cough.
Efficacious human metapneumovirus vaccine based on AI …
Jul 25, 2024 · The authors report an efficacious vaccine for human metapneumovirus based on a prefusion-stabilized fusion protein trimer that does not require a trimerization domain, designed using an AI ...
Recent vaccine development for human metapneumovirus - PMC
Although hMPV is a clinically important pathogen, no vaccine is currently available. hMPV comprises two genetic groups, A and B. Each group has two subgenetic classes, i.e. A1 and A2; B1 and B2. Currently, there are five contemporary circulating clades of hMPV, which have existed for decades (Gaunt et al., 2011; Papenburg et al., 2013).
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus …
Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) cause respiratory tract illness in children and the elderly. No licensed vaccines are available. In this phase 1, randomized, dose-ranging, first-in-human study, the safety, ...
Evaluation of a Live Attenuated Human Metapneumovirus Vaccine …
We conducted a phase I clinical trial of an experimental live attenuated recombinant human metapneumovirus (HMPV) vaccine (rHMPV-Pa) sequentially in adults, HMPV-seropositive children, and HMPV-seronegative children, the target population for ...
Everything you need to know about human metapneumovirus …
Jan 10, 2025 · Even though the risk of a metapneumovirus pandemic is remote, the virus can cause serious disease in some people, and unpleasant symptoms in many others. With no vaccine available to prevent human metapneumovirus or specific antiviral drug to treat it, the best strategy is to try and avoid catching it.
Mucosal bivalent live attenuated vaccine protects against human ...
Jun 19, 2024 · Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses and have the potential to protect against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV),...
Neutralising antibodies against human metapneumovirus
Jul 24, 2023 · Neutralising monoclonal antibodies (nMAbs) are the core effectors of vaccines and are essential therapeutic immune drugs against infectious pathogens. The development of nMAbs against hMPV has accelerated in recent years as a result of breakthroughs in viral fusion (F) protein structural biology and experience with hRSV and other enveloped viruses.
Recent vaccine development for human metapneumovirus
This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.